Catalyst Pharmaceuticals, Inc. (CPRX): Charles B O’keeffe , director of Catalyst Pharmaceuticals, Inc. purchased 20,000 shares on Jul 12, 2016. The Insider buying transaction was reported by the company on Jul 12, 2016 to the Securities and Exchange Commission. The shares were purchased at $0.81 per share for a total value of $16,272.00 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Jun 14, 2016, Donald A Denkhaus (director) purchased 50,000 shares at $0.65 per share price.On Jun 14, 2016, Patrick J Mcenany (CEO) purchased 105,300 shares at $0.65 per share price.Also, On Apr 27, 2016, Charles B O’keeffe (director) purchased 20,000 shares at $0.60 per share price.On Mar 17, 2016, Philip H Coelho (director) purchased 10,000 shares at $1.06 per share price.
Catalyst Pharmaceuticals Inc: On Monday, Jul 11, 2016 heightened volatility was witnessed in Catalyst Pharmaceuticals Inc which led to swings in the share price. The shares opened for trading at $0.81 and hit $0.8369 on the upside , eventually ending the session at $0.8009, with a gain of 0.11% or 0.0009 points. The heightened volatility saw the trading volume jump to 4,16,266 shares. The 52-week high of the share price is $5.8 and the company has a market cap of $66 M . The 52-week low of the share price is at $0.51.
Company has been under the radar of several Street Analysts.Catalyst Pharmaceuticals Inc is Downgraded by Piper Jaffray to Neutral while Lowering the Price Target of the company shares to $ 1 from a previous price target of $6 . Earlier the firm had a rating of Overweight on the company shares. The Rating was issued on Apr 26, 2016.
Catalyst Pharmaceuticals Inc. formerly Catalyst Pharmaceutical Partners Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing therapies for people with rare debilitating diseases. The Company has three drugs in development: Firdapse CPP-109 and CPP-115. Firdapse is used for the treatments of lambert-eaton myasthenic syndrome (LEMS) and congenital myasthenic syndromes (CMS). CPP-115 is used for the treatment of addiction and epilepsy. CPP-109 is used to treat addiction. The Company is conducting a Phase III trial to determine the safety and efficacy of Firdapse in the treatment of LEMS. CPP-115 has been granted Orphan Drug Designation by the food and drug administration (FDA) for the treatment of infantile spasms and Orphan Medicinal Product Designation in the European Union for West syndrome (a form of infantile spasms).